PYRIDOYRAZINONES AS PDE-5 INHIBITORS

Compounds, and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R3, R4, X6, Y6, R6, and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BROWN, DAVID, LOUIS, MOLYNEAUX, JOHN, MAJOR, PHILLIPS, CHRISTOPHER, JACOBSEN, ERIC, JON, MISCHKE, BRENT, VIRGIL, TOLLEFSON, MICHAEL, BRENT, BROWN, DAVID, GRAHAM, FRESKOS, JOHN, NICHOLAS, FOBJAN, YVETTE, MARLENE, PALMER, MICHAEL, JOHN, WALKER, JOHN, KEITH, BELL, ANDREW, SIMON, HUGHES, ROBERT, CRAIG, OWEN, DAFYDD, RHYS
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compounds, and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R3, R4, X6, Y6, R6, and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed. L'invention concerne des composés et des sels pharmaceutiquement acceptables de ceux-ci. Ces composés ont la structure représentée par formule I, dans laquelle R2, R3, R4, X6, Y6, R6 et R8 sont tels que définis dans le descriptif. Des compositions pharmaceutiques correspondantes, des méthodes de traitement, des procédés de synthèse et des produits intermédiaires sont également décrits.